HYTM Hythiam tgt raised to $15 from $12 at UBS (7.25 )
UBS raises their tgt on HYTM to $15 from $12 saying they are in ongoing contact with five of Hythiam's physician licensees. In sum, the firm says these physicians have reported to them that greater than 70% of the over 250 patients that they have treated with the PROMETA protocol experienced an elimination/reduction in cravings. They have also been in contact with Dr. Juan Legarda who reported to them similar results in over 500 patients. The firm continues to expect Hythiam will be issued patents over the exclusive use of PROMETA based on their own patent study in which they retained outside legal counsel.